TY - JOUR
T1 - Cancer immunotherapy
T2 - moving forward with peptide T cell vaccines
AU - Kumai, Takumi
AU - Fan, Aaron
AU - Harabuchi, Yasuaki
AU - Celis, Esteban
N1 - Funding Information:
This work was supported by grant from the National Cancer Institute of the National Institutes of Health, R01CA157303, and by start-up funds from the Georgia Cancer Center and the Georgia Research Alliance (GRA).
Publisher Copyright:
© 2017 Elsevier Ltd
PY - 2017/8
Y1 - 2017/8
N2 - Recent advances in cancer immunology, such as the discovery of immune checkpoint inhibitors, have validated immune cells as potential key players for effective cancer treatment. The efficacy of these therapies seems to be codependent on a tumor-reactive T lymphocyte response. For many years, numerous attempts and strategies in developing vaccines to generate tumor-reactive T cells have yielded poor results in the clinic due to suboptimal immunogenicity and the inability to overcome an immunosuppressive tumor microenvironment. In this review, we summarize past and current advances in T cell vaccines and describe our experience in developing optimized methods for antigen/adjuvant selection and vaccine administration in order to induce powerful anti-tumor responses.
AB - Recent advances in cancer immunology, such as the discovery of immune checkpoint inhibitors, have validated immune cells as potential key players for effective cancer treatment. The efficacy of these therapies seems to be codependent on a tumor-reactive T lymphocyte response. For many years, numerous attempts and strategies in developing vaccines to generate tumor-reactive T cells have yielded poor results in the clinic due to suboptimal immunogenicity and the inability to overcome an immunosuppressive tumor microenvironment. In this review, we summarize past and current advances in T cell vaccines and describe our experience in developing optimized methods for antigen/adjuvant selection and vaccine administration in order to induce powerful anti-tumor responses.
UR - http://www.scopus.com/inward/record.url?scp=85024864255&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85024864255&partnerID=8YFLogxK
U2 - 10.1016/j.coi.2017.07.003
DO - 10.1016/j.coi.2017.07.003
M3 - Review article
C2 - 28734176
AN - SCOPUS:85024864255
SN - 0952-7915
VL - 47
SP - 57
EP - 63
JO - Current Opinion in Immunology
JF - Current Opinion in Immunology
ER -